Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + acalabrutinib for high grade B-cell lymphoma
ACTRN12621000507886Phase 2Completed
- Sponsor
- The University of Sydney
- Start
- Sep 2021
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab and acalabrutinib in large-cell lymphoma and Transformed low-grade B-cell lymphoma (TLGBL), sponsored by The University of Sydney. Primary endpoint: Objective tumor response. Started Sep 2021; status: completed.
02
Drugs
durvalumabacalabrutinib
03
Conditions
large-cell lymphomaTransformed low-grade B-cell lymphoma (TLGBL)
Beyond the preview
Go deeper on ACTRN12621000507886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000507886.